Skip to main content

Advertisement

Table 2 Quality assessment of the included studies

From: Cetuximab for esophageal cancer: an updated meta-analysis of randomized controlled trials

Bias Selection bias Performance bias Attrition bias Reporting bias (no selective reporting) Detection bias Study quality (score)
Study Adequate random sequence generation Similar baseline condition Adequate allocation concealment Adequate participant blinding Adequate provider blinding Similar or no co-interventions Acceptable compliance Acceptable drop-out rate intention-to-treat analysis Adequate outcome assessor blinding Similar timing of outcome assessment
Studies included non-metastatic esophageal cancer
 Rades et al. (2014) [23] Unclear Unclear Unclear Unclear Unclear Yes Yes Unclear Yes Yes Unclear Yes Moderate (5)
 Zhang et al. (2014) Unclear Unclear Unclear Unclear Unclear Yes Unclear Yes Yes Yes Unclear Yes Moderate (5)
 Crosby et al. (2017) [21] Yes Yes Yes No Unclear Yes No Yes Yes Yes Unclear Yes high (8)
 Ruhstaller et al. (2017) Unclear Yes Unclear Unclear Unclear Yes Yes Yes Yes Yes Unclear Yes Moderate (7)
 Suntharalingam et al. (2017) [28] Unclear Yes Unclear Unclear Unclear Yes Yes Yes Yes Yes Unclear Yes Moderate (7)
Studies included metastatic esophageal cancer
 Lorenzen et al. (2009) [14] Unclear Yes Unclear Unclear Unclear Yes Yes Yes Yes Yes Unclear Yes Moderate (7)
 Chen et al. (2014) [22] Unclear Yes Unclear Unclear Unclear Yes Unclear Unclear Yes Yes Unclear No Low (4)
 Feng et al. (2017) [25] Yes Yes Unclear Unclear Unclear Yes Unclear Yes Yes Yes Unclear Yes Moderate (7)
 Yang et al. (2017) [26] Unclear Yes Unclear Unclear Unclear Yes Unclear Yes Yes Yes Unclear Yes Moderate (6)
 Lu et al. (2017) [16] Yes Yes Unclear Unclear Unclear Yes Unclear Yes Yes Yes Unclear Yes Moderate (7)